Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.66 |
| ▸ | NPBWR1 | P48145 | 9/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.55 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033887 | 0.82 | RAB9A (0.66) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL31277650 | 0.80 | NPC1 (1.00) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL3031931 | 0.80 | NPC1 (1.00) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL13219656 | 0.76 | NPBWR1 (0.77) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL18446084 | 0.74 | RAB9A (0.78) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL3028307 | 0.72 | RAB9A (0.66) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL18445806 | 0.72 | RAB9A (0.74) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL18446182 | 0.71 | NPC1 (0.64) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL11785004 | 0.71 | RAB9A (0.67) | NPC1RAB9APAX8NPBWR1MCHR1 | |
| SCHEMBL13219325 | 0.70 | RAB9A (0.71) | NPC1RAB9APAX8NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2518063-B1 | Pyridazinones and furan-containing compounds | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2518063-B1 | Pyridazinones and furan-containing compounds | SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2099770-B1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN KETTERING INST CANCER (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2518063-A1 | Pyridazinones and furan-containing compounds | Sloan-Kettering Institute For Cancer Research (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2518063-A1 | Pyridazinones and furan-containing compounds | Sloan-Kettering Institute For Cancer Research (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| EP-2099770-A2 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | Sloan-Kettering Institute for Cancer Research (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008080056-A2 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008080056-A2 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | NPC1 2857/4885RAB9A 3655/4885PAX8 2327/4885 |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | NPC1 2857/4885RAB9A 3655/4885PAX8 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.